Aller au contenu
Global sound
The Bio Report

The Bio Report

A Billion-Dollar Bet on AI-First Drug Development

· 47 min · Épisode 159

Notes d’épisode

Despite the emergence of new modalities and drug development technologies, the cost and time to produce new therapies has changed little, and failure rates remain high. Xaira aims to change that with a systematic, AI‑driven approach that tackles three pervasive bottlenecks—choosing the right targets, designing the right molecules, and matching the right patients—by running as much work as possible in silico and using high‑dimensional causal datasets to train “virtual cell” foundation models. The company is initially focusing on high‑value, historically undruggable targets and ultimately on building a pipeline of differentiated biologics. We spoke with Marc Tessier‑Lavigne, co‑founder and CEO of Xaira, about applying end‑to‑end AI across target discovery, molecular design, and patient stratification; the company’s more than $1 billion in funding, and how it seeks to enable a new generation of scientists fluent in both AI and biology.

Site web: thebioreport.podbean.com

En direct, dernière heure : 10 501 titres sur 4 313 stations dans 115 pays

Découvrez le monde par la radio

Plus de façons de découvrir (7)

Vous avez entendu quelque chose de bien ? Enregistrez-le, ou ouvrez-le directement dans Spotify.

★ Artiste de la semaine La plus forte progression à la radio cette semaine
Ton titre ici ? À partir de € 9 par semaine →
Radio Comunidad de FeContinuer l’écoute